Trodelvy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of metastatic breast cancer, advancements in monoclonal antibody engineering, expansion of oncology clinical trials, growing adoption of targeted cancer therapies, improved regulatory pathways for oncology drugs.

The growth in the forecast period can be attributed to expansion of personalized cancer treatment protocols, rising investments in adc pipeline development, increasing use of biomarker-driven therapies, advancements in linker and payload technologies, growing demand for improved cancer survival outcomes. Major trends in the forecast period include increasing adoption of antibody drug conjugate therapies, rising focus on targeted oncology treatments, expansion of trop-2 targeted therapeutics, growing use of precision oncology approaches, enhanced drug delivery mechanisms.

The rising incidence of breast cancer is expected to drive the growth of the Trodelvy market in the coming years. Breast cancer occurs when malignant cells develop in breast tissues and is among the most common cancers globally, affecting women primarily and, less frequently, men. The increase in breast cancer cases is linked to genetic factors, lifestyle changes, and greater awareness, leading to higher investments in advanced treatments and healthcare infrastructure worldwide. Trodelvy provides targeted therapy for advanced or metastatic breast cancer, improving survival outcomes and addressing the growing healthcare needs associated with its high prevalence. For example, in 2024, according to the American Cancer Society, a US-based nonprofit organization, approximately 313,510 new breast cancer cases were diagnosed, up from 300,590 cases in 2023. Therefore, the rising incidence of breast cancer is driving the Trodelvy market.

The rising prevalence of chronic diseases is expected to support the growth of the Trodelvy market. Chronic diseases are long-term health conditions that often cannot be cured but can be managed, including cancer, cardiovascular disorders, and metabolic diseases, which frequently require specialized treatments such as advanced targeted therapies. Factors such as aging populations, sedentary lifestyles, unhealthy diets, and environmental risks contribute to the growing prevalence of chronic diseases. This trend boosts demand for Trodelvy by increasing the need for innovative oncology treatments that precisely target tumor cells, minimize side effects, and improve patient outcomes. For instance, in April 2025, according to the NHS Confederation, a UK-based national association, it is estimated that by 2035, 17% of the UK population could have four or more chronic conditions. Therefore, the rising prevalence of chronic diseases is driving the growth of the Trodelvy market.

Key companies in the Trodelvy market are expanding treatment indications to provide a broader range of patients with advanced, targeted therapies that improve survival and quality of life. This strategy addresses unmet medical needs across multiple oncology indications, enhancing the drug’s clinical impact and commercial potential. For example, in February 2023, Gilead Sciences Inc., a US-based pharmaceutical company, received expanded approval in the United States for Trodelvy to treat HR-positive and HER2-negative metastatic breast cancer, significantly broadening its market and addressing a larger patient population. This strategic move positions Trodelvy to compete more effectively in the broader breast cancer treatment landscape.

Major companies operating in the trodelvy market are Gilead Sciences Inc.

North America was the largest region in the trodelvy market in 2025. The regions covered in the trodelvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the trodelvy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the trodelvy market by increasing costs of imported monoclonal antibodies, cytotoxic payload components, specialized manufacturing equipment, and sterile filling systems used in adc production. Oncology drug manufacturers in North America and Europe are most affected due to dependence on global biologics supply chains, while Asia-Pacific faces higher export and formulation costs. These tariffs are increasing production expenses and pricing pressures for advanced cancer therapies. At the same time, they are encouraging regional manufacturing expansion, domestic biologics innovation, and investments in local adc production infrastructure.

The trodelvy market research report is one of a series of new reports that provides trodelvy market statistics, including trodelvy industry global market size, regional shares, competitors with a trodelvy market share, detailed trodelvy market segments, market trends and opportunities, and any further data you may need to thrive in the trodelvy industry. This trodelvy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Trodelvy is an antibody-drug conjugate (ADC) that links a targeted monoclonal antibody with a chemotherapy agent. The monoclonal antibody binds to Trop-2, a protein frequently overexpressed on certain cancer cells, allowing the chemotherapy to be delivered directly to these cells.

The primary indications for Trodelvy include metastatic triple-negative breast cancer (mTNBC), HR-positive or HER2-negative breast cancer, and metastatic urothelial cancer. Metastatic triple-negative breast cancer (mTNBC) is a subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). Trodelvy is distributed through hospitals, clinics, and retail and specialty pharmacies, and is used by end users including adult and geriatric patients.

The trodelvy market consists of sales of companion diagnostic tests and antibody-drug conjugates, and adjunctive therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.